Tafamidis in Transthyretin Amyloid Cardiomyopathy: Effects on Transthyretin Stabilization and Clinical Outcomes

Circulation: Heart Failure

Volumn 8, Issue 3, 2015, Pages 519-526

  Maurer, Mathew S ^a   Grogan, Donna R ^b   Judge, Daniel P ^b,c   Mundayat, Rajiv ^b   Packman, Jeff ^b   Lombardo, Ilise ^b   Quyyumi, Arshed A ^d   Aarts, Janske ^b   Falk, Rodney H ^e  

^a NewYork Presbyterian Hospital   (United States)

^b PFIZER INC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

amyloid; cardiomyopathies; clinical trial; heart failure

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; PREALBUMIN; TAFAMIDIS; TROPONIN I; TROPONIN T; BENZOXAZOLE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; BODY WEIGHT; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; COMORBIDITY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE WALL; HEART MUSCLE BIOPSY; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; NEW-ONSET ATRIAL FIBRILLATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; Q WAVE; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SUPRAVENTRICULAR TACHYCARDIA; TRANSTHYRETIN AMYLOID CARDIOMYOPATHY; TREATMENT OUTCOME; WILD TYPE; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; HEART MUSCLE; METABOLISM; MUTATION; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STABILITY; TIME; UNITED STATES;

AGED; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; CARDIOMYOPATHIES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MUTATION; MYOCARDIUM; PREALBUMIN; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, QUATERNARY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84938525710     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000890     Document Type: Article

References (29)

1. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol. 1978;121:339-356.
2. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: a and retinol-binding protein. Science. 1995;268:1039-1041.
3. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem. 2001;276:27207-27213. doi: 10.1074/jbc.M101024200.
4. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA. 2002;99(suppl 4):16427-16432. doi: 10.1073/pnas.202495199.
5. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010;52:347-361. doi: 10.1016/j.pcad.2009.11.007.
6. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398-408. doi: 10.1038/nrcardio.2010.67.
7. Buxbaum J, Jacobson DR, Tagoe C, Alexander A, Kitzman DW, Greenberg B, Thaneemit-Chen S, Lavori P. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol. 2006;47:1724-1725. doi: 10.1016/j.jacc.2006.01.042.
8. Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J. 2010;159:864-870. doi: 10.1016/j.ahj.2010.02.006.
9. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60:765-774. doi: 10.1111/j.1532-5415.2011.03868.x.
10. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chainassociated amyloidosis. Arch Intern Med. 2005;165:1425-1429. doi: 10.1001/archinte.165.12.1425.
11. Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O'Hara C, Seldin DC, Skinner M. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158:607-614. doi: 10.1016/j.ahj.2009.08.006.
12. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222-228. e1. doi: 10.1016/j.ahj.2012.04.015.
13. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2:e000098. doi: 10.1161/JAHA.113.000098.
14. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, Naka Y, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation. 2007;83:539-545. doi: 10.1097/01.tp.0000255567.80203.bd.
15. Pilato E, Dell'Amore A, Botta L, Arpesella G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur J Cardiothorac Surg. 2007;32:180-182. doi: 10.1016/j.ejcts.2007.03.023.
16. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629-9634. doi: 10.1073/pnas.1121005109.
17. Hammarström P, Jiang X, Deechongkit S, Kelly JW. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry. 2001;40:11453-11459.
18. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicąõ IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785-792. doi: 10.1212/WNL.0b013e3182661eb1.
19. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245-1255.
20. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
21. Januzzi JL Jr, Sakhuja R, O'donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA Jr, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315-320. doi: 10.1001/archinte.166.3.315.
22. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319-328. doi: 10.1002/ajh.20381.
23. Berk JL, Suhr OB, Sekijima Y, Yamashita T, Heneghan M, Zeldenrust SR, Ando Y, Ikeda S, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Dyck PJ, Obici L; Familial Amyloidosis Consortium. The Diflunisal Trial: study accrual and drug tolerance. Amyloid. 2012;19 Suppl 1:37-38. doi: 10.3109/13506129.2012.678509.
24. Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6:1011-1020. doi: 10.1007/s12265-013-9512-x.
25. Lozeron P, Theaúdin M, Mincheva Z, Ducot B, Lacroix C, Adams D; French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20:1539-1545. doi: 10.1111/ene.12225.
26. Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012;19(suppl 1):43-44. doi: 10.3109/13506129.2012.673140.
27. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819-829. doi: 10.1056/NEJMoa1208760.
28. Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging health. 2013;9:229-235. doi: 10.2217/ahe.13.10.
29. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909. doi: 10.1056/NEJM199709253371306.